Algert Global LLC Immunovant, Inc. Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Algert Global LLC holds 36,969 shares of IMVT stock, worth $1.02 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

36,969

Previous 120,938 69.43%

Holding current value

$1.02 Million

Previous $3.19 Million 66.99%

% of portfolio

0.03%

Previous 0.11%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$27.51 - $27.51 $2.31 Million - $2.31 Million	-83,969 Reduced 69.43%	36,969 $1.05 Million
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $1.74 Million - $2.19 Million	69,278 Added 134.1%	120,938 $3.19 Million
Q1 2024 May 14, 2024	BUY	$30.27 - $43.79 $60,509 - $87,536	1,999 Added 4.03%	51,660 $1.67 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $432,328 - $610,175	-13,808 Reduced 21.76%	49,661 $2.09 Million
Q3 2023 Nov 13, 2023	SELL	$18.55 - $39.96 $300,324 - $646,952	-16,190 Reduced 20.32%	63,469 $2.44 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $574,674 - $961,162	40,470 Added 103.27%	79,659 $1.51 Million
Q1 2023 May 12, 2023	BUY	$15.27 - $19.72 $598,416 - $772,807	39,189 New	39,189 $608,000
Q3 2022 Nov 15, 2022	SELL	$3.93 - $6.37 $170,793 - $276,833	-43,459 Reduced 34.44%	82,741 $462,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $34,229 - $57,217	-10,127 Reduced 7.43%	126,200 $492,000
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $689,814 - $1.2 Million	136,327 New	136,327 $751,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $201,257 - $326,432	-28,710 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$9.4 - $16.85 $360,988 - $647,090	-38,403 Reduced 57.22%	28,710 $303,000
Q1 2021 May 14, 2021	BUY	$13.08 - $49.6 $877,838 - $3.33 Million	67,113 New	67,113 $1.08 Million

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Immunovant, Inc. Transaction History